← Back to Search

Cancer Vaccine

Vaccine Immunotherapy for Pediatric Brain Cancer (Re-MATCH Trial)

Phase 2

Waitlist Available

Led By Duane Mitchell, MD, PhD

Research Sponsored by University of Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be ≤ 30 years of age

Patients must have histologically confirmed recurrent MB/PNET that is a first relapse/progression after completion of definitive radiotherapy +/- craniospinal irradiation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months)

Awards & highlights

Re-MATCH Trial Summary

This trial will use immunotherapy to treat brain tumors in children.

Who is the study for?

This trial is for children and young adults up to 30 years old with a first recurrence of medulloblastoma or primitive neuroectodermal tumors after radiotherapy. Participants need stable neurological function, adequate blood counts, normal kidney and liver function, and must agree to use birth control. Those with genetic risks for radiation-induced cancers are also eligible.Check my eligibility

What is being tested?

The study tests tumor-specific immune cells (TTRNA-xALT) and dendritic cell vaccines (TTRNA-DCs) on about 35 patients with recurrent brain tumors. It aims to see how these immunotherapies affect the tumor's progression based on prior success in adult cancer treatments.See study design

What are the potential side effects?

While specific side effects aren't listed here, immunotherapy can generally cause flu-like symptoms, fatigue, rash, fever, chills, weakness or dizziness. More serious reactions might include changes in blood pressure or heart rate.

Re-MATCH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 30 years old or younger.

Select...

My cancer has returned after initial radiation treatment.

Select...

I can do most activities but may need assistance.

Select...

My cancer has returned, and I can't have radiation due to a genetic risk of more cancer.

Select...

I or my guardian agree to a stem cell or bone marrow collection if needed.

Re-MATCH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

12 Month Progression-free Survival (PFS-12)

Secondary outcome measures

Characterize Immunologic Phenotype of Lymphocyte Subsets and NK Cells

Correlate Magnitude and Persistence of Anti-tumor Humoral or Cellular Immunity With Clinical Outcome

Determine of Overall Survival Rate

+2 more

Re-MATCH Trial Design

2Treatment groups

Experimental Treatment

Group I: Group BExperimental Treatment2 Interventions

NMA Salvage chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.

Group II: Group AExperimental Treatment2 Interventions

High dose chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor

1,340 Previous Clinical Trials

715,670 Total Patients Enrolled

1 Trials studying Neuroectodermal Tumors

24 Patients Enrolled for Neuroectodermal Tumors

United States Department of DefenseFED

861 Previous Clinical Trials

227,168 Total Patients Enrolled

1 Trials studying Neuroectodermal Tumors

13 Patients Enrolled for Neuroectodermal Tumors

Duane Mitchell, MD, PhDPrincipal InvestigatorUniversity of Florida

4 Previous Clinical Trials

213 Total Patients Enrolled

Media Library

TTRNA-DCs (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT01326104 — Phase 2

Neuroectodermal Tumors Research Study Groups: Group A, Group B

Neuroectodermal Tumors Clinical Trial 2023: TTRNA-DCs Highlights & Side Effects. Trial Name: NCT01326104 — Phase 2

TTRNA-DCs (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01326104 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor recruiting participants at the present time?

"Unfortunately, clinicaltrials.gov does not indicate that this investigation is actively recruiting at this juncture. This trial was initially posted on September 7th 2010 and last modified on the 1st of July 2022; however, 87 other trials are still seeking participants right now."

Answered by AI

Has the FDA validated TTRNA-DCs for therapeutic application?

"Since this is a Phase 2 trial, and there is no current data attesting to its efficacy but some evidence of safety, our team at Power has assigned TTRNA-DCs a score of 2 on the 1 - 3 scale."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor

2010. "Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01326104.

All > Medulloblastoma